Review papers with raw data transparency

Paper Review: Mechanisms of P. aeruginosa resistance to Type VI Secretion System attacks

Major claims & the supporting evidence (paper data)

• GacA/GacS regulon is central to T6SS resistance: CRISPRi hits and ΔgacA knockout increased susceptibility ~100-fold to A. baylyi and V. cholerae; proteomics shows decreased abundance of GacA-regulated proteins in ΔgacA proteome Preprint — GacA evidence
• mag operon (magD) protects primarily against peptidoglycan-targeting effectors: loss of magD increases susceptibility to VgrG3 (V. cholerae) and Tae1 (A. baylyi) in CFU and CPRG lysis kinetics Preprint — magD evidence
• OprF and OM-PG anchoring provide broad resistance: ΔoprF is hypersensitive to T6SS attacks across attacker species/effectors; complementation with WT oprF rescues phenotype but OprF-R296E (PG-binding deficient) fails, implicating OM-PG anchoring Preprint — OprF evidence
• Effector-type specificity: arc1A/arc3A/aas defend specifically against lipase effectors; magD defends against PG hydrolases; OprF is more generalist — evidence comes from targeted attacker effector mutants and CPRG assays Preprint — effector specificity
• T6SS resistance correlates with antibiotic susceptibility changes: ΔoprF and ΔmagD showed altered MIC/growth phenotypes to tetracycline, piperacillin, chlorhexidine, colistin (mixed directionality), suggesting envelope integrity influences both T6SS and antibiotic responses Preprint — antibiotic interactions

Critical appraisal — strengths

• Genome-scale CRISPRi in a H1-T6SS-deficient background isolates prey-side protective pathways while avoiding tit-for-tat retaliation confounders Preprint — experimental design
• Orthogonal validation (CFU, CPRG lysis kinetics, complementation, proteomics) strengthens causal inference for top hits.
• Cross-attacker approach (A. baylyi and V. cholerae) distinguishes effector-class specificity vs general defenses.

Critical appraisal — limitations & blind spots

• In vitro attacker selection limits generality: only A. baylyi ADP1 and V. cholerae 2740-80 (and limited B. thailandensis tests) were used; T6SS effector repertoires across environments are diverse, so protective mechanisms may be attacker- or effector-specific. This is acknowledged by authors and consistent with prior literature showing species-specificity of defenses Preprint — generality note
• CRISPRi knockdown variability: incomplete knockdown (vs knockout) can yield partial phenotypes and false negatives; sgRNA representation and efficiency biases can shape hit lists (authors used MAGeCK with median normalization and 3 biological replicates, but residual bias remains).
• Suppressor evolution complicates interpretation: ΔoprF revertants acquired gacS deletions that restored growth but not T6SS resistance — demonstrating selection pressures in culture and the need for careful interpretation of genetic interactions and pleiotropy.
• Mechanistic gaps: magD homology to α2-macroglobulin is intriguing but bacterial MagD lacks key catalytic residues; the molecular mechanism of MagD protection against PG hydrolases remains unresolved — no direct biochemical trap or binding assay shown yet (future biochemical or structural work needed).
• Antibiotic trade-off data are preliminary: observed antibiotic susceptibility shifts are intriguing but variable (ΔoprF shows both sensitization and resistance depending on drug) and require quantitative MICs across replicates, complemented by mechanistic assays (LPS modification, OM permeability, efflux changes) to be interpretable clinically.

Where the paper opens important mechanistic questions

• MagD molecular mechanism: Is MagD a physical trap for PG hydrolases or does it act by recruiting periplasmic repair functions? Bacterial α2-macroglobulin-like proteins lack eukaryotic active sites; targeted biochemical binding assays or co-IP with effectors are needed.
• OprF-mediated resistance mechanism: Is OM-PG anchoring preventing effector penetration mechanically, or modulating envelope stress signaling that activates other defenses? Need assays of OM stiffness, Lpp/Lpp-like lipoprotein status, and periplasmic enzyme diffusion.
• GacA regulon interplay: Which specific GacA-controlled genes (beyond arc and mag) are critical? Global RNA-seq of ΔgacA in the exact conditions of competition would deconvolute direct vs indirect effects.

Concrete, high-value experiments to close gaps

1. Biochemical interaction tests: Purify MagD and representative PG-targeting effectors (VgrG3/Tae1) and test binding/inhibition (pull-down, SPR, enzyme kinetics) to test the trap-hypothesis.
2. Mechanical/biophysical assays for OprF: Atomic force microscopy (AFM) or osmotic shock assays comparing wild-type, ΔoprF, and OprF-R296E to quantify OM stiffness and permeability; dye-uptake/fluorescent probes for periplasmic leakage during attacker contact.
3. RNA-seq during competition: Time-resolved transcriptomics (wild-type vs ΔgacA vs ΔoprF) during attacker contact (early time points, e.g., 5, 15, 60 min) to identify dynamic defensive responses and whether GacA activity triggers envelope stress or metabolic remodeling that enables survival.
4. In vivo / more diverse attacker panel: Test clinical and environmental T6SS-bearing strains (diverse effector repertoires) and in polymicrobial biofilm or infection models (e.g., CF sputum mimic) to assess ecological relevance and antibiotic trade-offs in a host-like context.

Reproducibility & data transparency

• Raw CRISPRi sequencing data (ENA PRJEB84063), proteomics (MassIVE MSV000096798) and Zenodo records are listed in the manuscript; MAGeCK pipeline parameters (median normalization, FDR 0.25) are stated — good practice for reproducibility Preprint — data availability & pipelines
• Potential missing details to enable step-by-step reproduction: per-sgRNA depletion tables, exact MAGeCK QA plots, full MIC tables with replicates, and raw blot/images (source data) should be in a public supplementary repository (Zenodo entries may contain these — check deposit).